# Karenitecin in Pediatric Patients With Refractory or Recurrent Solid Tumors N10010)

> **NCT00586560** · PHASE1 · COMPLETED · sponsor: **Baylor College of Medicine** · enrollment: 15 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Kareniticin and cyclophosphamide

## Key facts

- **NCT ID:** NCT00586560
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2012-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00586560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00586560, "Karenitecin in Pediatric Patients With Refractory or Recurrent Solid Tumors N10010)". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00586560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*